RESUMO
ETHNOPHARMACOLOGICAL RELEVANCE: Chronic periodontitis is an inflammatory process of the oral cavity that is caused by different reasons. Streptococcus mutans bacteria is the main cause of the disease. Scrophularia striata in Iranian traditional medicine is used to heal inflammation of gum and mouth. Also, In vitro anti-bacterial effect of S. striata in S. mutans have been demonstrated. AIM OF THE STUDY: Clinical, in vitro and chemical constituent studies of S. striata on chronic periodontitis disease. MATERIALS AND METHODS: This study is a randomized clinical trial that was performed in Dental College, Hamadan University of Medical Sciences. Fifty patients with chronic periodontitis (20-50 years old) were selected and the study was approved and registered in Iranian Registry of Clinical Trials as number IRCT2015081323468N1 prior to the experiment. The 50 patients were divided into two groups. One group used herbal mouthwash that was made from hydro alcoholic extract of S. striata and another group used Irsha mouthwash (Iranian form of Listerine mouthwash). Patients were followed up after two weeks and four weeks of using mouthwash for assessment of plaque index (PI), pocket depth (PD), bleeding on probing (BOP) and counting Streptococcus mutans. The mouthwash was standardized according to gallic acid, quercetin and apigenin reference using the RP-HPLC method. The total phenolic and flavonoids contents were also determined spectrophotometerically. RESULTS: S. striata in the short term, improve plaque index, pocket depth and bleeding on probing but the number of Streptococcus mutans changed significantly in the long term and is more potent in comparison to Irsha mouthwash. The mouthwash was standardized according to gallic acid, quercetin and apigenin standard (3, 24, 11⯵g, respectively). The total phenolic and flavonoid content of mouthwash were 120.7⯵g GAE/100â¯cc and 78.6⯵g QE/100â¯cc respectively. CONCLUSIONS: S. striata mouthwash is effective in the treatment of chronic periodontitis disease and is more potent comparing the Iranian Irsha mouthwash.
Assuntos
Periodontite Crônica/tratamento farmacológico , Antissépticos Bucais/uso terapêutico , Extratos Vegetais/uso terapêutico , Scrophularia , Adulto , Índice de Placa Dentária , Feminino , Hemorragia/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Antissépticos Bucais/química , Compostos Fitoquímicos/análise , Compostos Fitoquímicos/uso terapêutico , Extratos Vegetais/química , Streptococcus mutans/efeitos dos fármacos , Streptococcus mutans/crescimento & desenvolvimento , Resultado do Tratamento , Adulto JovemRESUMO
OBJECTIVE: To identify and classify Iranian isolates of diarrheagenic Escherichia coli (E. coli) on the basis of presence of virulence genes and to determine antibiotic susceptibility of isolated strains. METHODS: The current cross-sectional study was conducted in 2005 at the Pasteur Institute, Tehran, Iran. One hundred and ninety-three diarrheagenic E. coli isolated from diarrheal patients in different regions of Iran were included in current study. Virulence factor genes for diarrheagenic E. coli were detected by polymerase chain reaction. RESULTS: Of the 193 diarrheagenic E. coli detected by PCR, 86 (44.5%) were Shiga toxin-producing E. coli STEC, 74 (38.4%) enteropathogenic E. coli EPEC, 19 (9.8%) enteroaggregative E. coli, and 14 (7.3%) enterotoxigenic E. coli isolates. Susceptibility to 12 clinically important antimicrobial agents was determined for 193 strains of diarrheagenic E. coli. A high incidence of resistance to tetracycline (63%), ampicillin (62%), streptomycin (56%), amoxicillin/clavulanic acid (44.5%), trimethoprim/sulfamethoxazole (39.5%), and cephalothin (37%) was observed. CONCLUSION: The STEC and EPEC strains with high resistance to tetracycline and ampicillin, but highly susceptible to quinolones are among the most important causative agent of diarrhea in Iran. This study suggests that antimicrobial resistance is widespread among E. coli strains colonizing Iranian patients. Guidelines for appropriate use of antibiotics in developing countries require updating.